Intelligent Bio-Systems Shifts Focus, Plans Launch of PinPoint Mini Sequencing Platform by 2012 | GenomeWeb

By Monica Heger

Intelligent Bio-Systems is developing a low-cost sequencing system that it claims is particularly suited for the clinical market and plans to commercially launch the system in 2012.

Steven Gordon, CEO of Waltham, Mass.-based IBS, disclosed the company's plans for the system at this month's X-Gen Congress meeting in San Diego. He said the company plans to line up early-access customers in the third or fourth quarter of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.